DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162439

Carvedilol versus beta-1 blockers as anti-hypertensive drugs in type-2 diabetes mellitus and pre-diabetic patients with features of metabolic syndrome: a meta-analysis

Sharanabasayyaswamy B. Hiremath, Srinivas Devendrappa Lokikere

Abstract


Background: It is unclear and contradictory on to whether carvedilol is preferable over beta-1 blockers as add-on drug in hypertensive pre-diabetic and diabetic patients with metabolic syndrome. The objective of this study was to compare the effects of carvedilol versus beta-1 blockers on hemodynamic parameters, indicators of insulin resistance and plasma lipid levels in hypertensive diabetic and pre-diabetic patients with features of metabolic syndrome.

Methods: Electronic database search in Pubmed, Cochrane library and EMBASE was conducted. Randomized or cross-over studies comparing effects of carvedilol against beta-1 blockers were included under analysis. Statistical analysis by inverse variance method and both random and fixed effect models was conducted by using RevMan 5.3.

Results: Six studies were eligible and included in the analysis. There was minor but significant decrease in SBP (mean difference, MD = -1.38mm Hg, 95% CI = -2.09,-0.66) and HbA1C% (MD = -0.21%, 95% CI -0.41 to -0.02) by carvedilol in patients with type-2 DM.

Conclusions: There is moderate quality of evidence to suggest that carvedilol has mild but significant SBP and HbA1C% lowering effect compared to beta-1 blockers in hypertensive patients with type-2 DM.


Keywords


Carvedilol, Beta-1 blockers, Type-2 DM, Hypertension, Metabolic syndrome

Full Text:

PDF

References


Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocr Metab. 2012;16:7-12.

Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013;3:1-58.

Israili ZH, Lyoussi B, Rafael HH, Velasco M. Metabolic syndrome: treatment of hypertensive patients. American Journal of Therapeutics. 2007;14:386-402.

Furberg CD, Wright JT, Davis B. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-97.

Yang Y, Wei RB, Wang ZC, Wang N, Gao YW, Li MX, et al. A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockerson insulin sensitivity in hypertensive patients without diabetes. Diabetes Res Clin Pract. 2015;107(3):415-23.

Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.

Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583-92.

Cooper-dehoff RM, Handberg EM, Mancia G, Zhou Q, Champion A, Legler UF, et al. INVEST revisited: a review of findings from the international verapamil SR-trandolapril study (INVEST). Expert Rev Cardiovasc Ther. 2009;7:1329-40.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047-56.

Agodoa L, Baigent C, Black H, Boissel JP, Brenner B. Effects of different blood pressure–lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med. 2005;165:1410-9.

Torres YC, Katholi RE. Novel treatment approaches in hypertensive type 2 diabetic patients. World J Diabetes. 2014;5:536-45.

Schachter M. Metabolic effects of moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab. 1999;1:317-22.

Hansson L. Therapy of hypertension and metabolic syndrome: today's standard and tomorrow's perspectives. Blood Press suppl. 1998;3:20-2.

Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-36.

Wright JT, Bakris GL, Bell DS, Fonseca V, Katholi RE, McGill JB, et al. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich). 2007;9:842-9.

Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, et al. Demographic analyses of the effects of carvedilol versus metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the glycemic effects in diabetes mellitus: carvedilol-metoprolol comparison in hypertensives (GEMINI) study. J Cardiometab Syndr. 2008;3:211-7.

Bell DS, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes Obes Metab. 2009;11:234-8.

Martsevich SY, Tolpygina SN. Comparison of the influence of long-term treatment based on carvedilol or bisoprolol on metabolic parameters in hypertensive patients with overweight or obesity. Results of the randomized open-label parallel-groups steppped trial CABRIOLET (part I). Rational Pharmacother Card. 2012;8:488-99.

Nancy GB, Robert AP. Meta-analysis: neither quick nor easy. BMC medical research methodology. 2002;2:1-9.

Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy MJ. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. AJH. 2007;20:777-83.

Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension a randomized, controlled trial. Ann Intern Med. 1997;126:955-9.

Ehmer B, van der Does R, Rudorf J. Influence of carvedilol on blood glucose and glycohaemoglobin al in non-insulin-dependent diabetics. Drugs. 1988;36:136-40.

Jacob S, Rett K, Wicklmayr M, Agrawal B, Auguatin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metaprolol study. Journal of hypertension. 1996;14:489-94.

Wong GWK, Laugerotte A, Wright JM. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Cochrane Database of Systematic Reviews. 2015;8:CD007449.

Chen JMH, Heran BS, Perez MI, Wright JM. Blood pressure lowering efficacy of beta-blockers as secondline therapy for primary hypertension. Cochrane Database of Systematic Reviews. 2010;1:CD007185.

Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-53.

Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews. 2012;11:CD002003.

Margolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721-8.

Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications. 2008;22:303-8.

Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968-73.